Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06190379 · ClinicalTrials.gov registry record · NA
Aromatherapy for Upper Respiratory Health
A NA study, sponsored by Nutraceuticals Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT06190379: Completed NA study, sponsored by Nutraceuticals Research Institute.
NCT06190379 is a NA study that has completed, run by Nutraceuticals Research Institute. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06190379, a NA study, has completed, sponsored by Nutraceuticals Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to confirm and quantify the effects of aromatherapy on respiratory health.
Primary Outcome
Respiratory symptoms are measured using the Franklin Immune Scale, Respiratory Subdomain, which documents the presence of over 20 symptoms, then rates them by severity. Lower scores mean lesser severity.
Interventions
- OTHER Placebo
- OTHER Essential oil blend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2023-04-08 |
| Phase | NA |
What the finished NCT06190379 record still lists
NCT06190379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06190379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06190379 about?
NCT06190379 is a clinical study titled "Aromatherapy for Upper Respiratory Health". The purpose of this study is to confirm and quantify the effects of aromatherapy on respiratory health.
What is the current status of trial NCT06190379?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2022-12-01. Estimated completion is 2023-04-08.
What interventions are being tested in trial NCT06190379?
The interventions under investigation include: Placebo (OTHER), Essential oil blend (OTHER).
Who is sponsoring clinical trial NCT06190379?
This trial is sponsored by Nutraceuticals Research Institute, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06190379's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI